

DAFTAR PUSTAKA

- Alwan, W., Frank O. N. 2015. Pathogenesis And Treatment Of Psoriasis: Exploiting Pathophysiological Pathways For Precision Medicine. *Clinical And Experimental Rheumatology*. 33(5):S2-S6. doi: 10.1083/nrdp.2016.82.
- Aneja, S.P.S., Gurcharan S. 2011. Cardiovascular Morbidity in Psoriasis. *Indian Journal of Dermatology*. 56(5):553-556. doi: 10.4103/0019-5154.87154.
- Astindari, S., Sandika W. 2014. Perbedaan Dermatitis Seboroik Dan Psoriasis Vulgaris Berdasarkan Manifestasi Klinis Dan Histopatologi. *Berkala Ilmu Kesehatan Kulit & Kelamin* 26(1): 72-78. doi: 10.20473/bikkk.V26.1.2014.1-7.
- Astrid, C., Ismiralda O.P., Kurniasih D.P. 2018. Perbedaan Tingkat Keparahan Psoriasis Pada Pasien Psoriasis Dengan dan Tanpa Fokal Infeksi. *Mandala Health Journal* 11(2): 80-94. doi: [10.20884/1.mandala%20health.2018.11.2.944](https://doi.org/10.20884/1.mandala%20health.2018.11.2.944)
- Bajaj, S., Gautam R.K., Khurana A., Arora P., Sharma N. 2017. Effect of Narrow Band Ultraviolet B Phototherapy on T Helper 17 Cell Specific Cytokines (Interleukins-17, 22 and 23) in Psoriasis Vulgaris. *Journal of Dermatological Treatment* 28(1): 14-17. doi: 10.1080/09546634.2016.1177162.
- Bélanger, A., Oliveira P., Maheux C., Pouliot M., R. 2016. Plaque Psoriasis: Understanding Risk Factors of This Inflammatory Skin Pathology. *Journal of Cosmetics, Dermatological Sciences and Applications* 6(2): 67-80. doi: 10.1046/j/1468-3083.2001.00192.x
- Cantika, A.S., Meillien H., Sudaryanto. 2012. Hubungan Derajat Keparahan Psoriasis Terhadap Kualitas Hidup Penderita. *Jurnal Media Medika Muda*. 1:1-13.
- Carretero, G., Puig L., Dehesa L., Carrascosa J.M. 2010. Guidelines on The Use of Methotrexate in Psoriasis. *Actas Dermosifiliogr*. 101(4): 600-613. doi: 10.1371/journal.pone.0194401.
- Chen, L., Tsai F. 2017. HLA-Cw6 And Psoriasis. *British Journal of Dermatology*. 3(5):543-78. doi: 10.1111/bjd.16083.
- Dahlan, M.S. 2009. *Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan*. Jakarta: Salemba Medika.
- Dahlan, M.S. 2014. *Statistika untuk Kedokteran dan Kesehatan Edisi 5*. Jakarta: Salemba Medika.

- Dogra, S., Mahajan R. 2013. Systemic Methotrexate Therapy for Psoriasis: Past, Present, Future. *Clin Exp Dermatol.* 38(6):573-88. doi: 10.1111/ced.12062.
- Drug Bank. 2019. *Methotrexate*. Drug Bank Canada.
- Elghandour, T.M., Youssef S.E.S., Aly D.G., Elhameed M.S.A., Moneim M.M.A. 2013. Effect of Narrow Band Ultraviolet B Therapy versus Methotrexate on Serum Levels of Interleukin-17 and Interleukin-23 in Egyptian Patients with Severe Psoriasis. *Dermatology Research and Practice* 2013. doi: 10.1155/2013/618269.
- Feldman, S. R., Bhaskar S., Jill A., Timothy H. 2018. Related to Inflammatory Bowel Disease in Patients With Moderate to Severe Psoriasis. *Journal Drug in Dermatology* 17(1): 1298-12. doi: 10.1016/j.aad.2016.10.027.
- Fontanez, A., Soler D.C., McCormick. 2016. Current Knowledge on Psoriasis and Autoimmune Disease. *Psoriasis: Target and Therapy* 6(1): 7–32. doi: 10.2147/PTT.S64950.
- Gelfand, J.M., Weinsten R., Porter S.B., Neimann A.L., Berlin J.A., Margolis D.J. 2005. Prevalence and Treatment of Psoriasis in The United Kingdom: A Population Based Study. *Arch Dermatol.* 141(12):1537-41. doi: 10.1001/archderm.141.12.1537.
- Goiabeira, M.F., Débora B.C.N., Adriana K.L.P.M., Samira O.S., Érica B.P., Yandra, S.E., *et al.* 2018. Assessment of Patients with Psoriasis Undergoing Treatment with Narrowband UVB Phototherapy in the State University of Pará, Brazil. *International Archives of Medicine* 11: 1–5. doi: 10.3823/2566.
- Goldsmith, L.A., Katz, S.I., Gilchrest, B.A., Paller, A.S., Leffell, D.J., Wolff, K. 2012. *Fitzpatrick's Dermatology in General Medicine*. 8th ed. New York:Mc Graw Hill co.
- Gu, X., Elisabet N., Philip J. C., Karin N. 2015. Oxidation Reduction Is a Key Process for Successful Treatment of Psoriasis by Narrow-Band UVB Phototherapy. *Acta Dermato-Venereologica* 95: 140–46. doi: 10.2340/00015555-1905.
- Guðjónsson, J.E., Helgi V., Ari K., Arna A. A.E, Hjaltey R., Jeffrey R. G., Kári S. 2002. "HLA-Cw6-Positive and HLA-Cw6-Negative Patients with Psoriasis Vulgaris Have Distinct Clinical Features". *Journal of Investigative Dermatology* 118: 362–65. doi: 10.1046/j.0022-202x.2001.01656.x.
- Guðjónsson, J. E. 2012. Psoriasis. Dalam: Goldsmith, L.A., Katz, S.I., Gilchrest, B.A., Paller, A.S., Leffell, D.J., Wolff, K. *Fitzpatrick's Dermatology in General Medicine*. 8th ed. New York:Mc Graw Hill co., pp. 197-231.

- Haider, S., Zarnaz W., Najam U.S., Farzana R. 2014. Efficacy of Methotrexate in Patients with Plaque Type Psoriasis. *Pakistan Journal of Medical Sciences* 30: 1050–53. doi: 10.12669/pjms.305.4451.
- High, W. A., James E. F. 2012. Cytotoxic and Anti Metabolite Agents. Dalam: Goldsmith, L.A., Katz, S.I., Gilchrest, B.A., Paller, A.S., Leffell, D.J., Wolff, K. *Fitzpatrick's Dermatology in General Medicine*. 8th ed. New York:Mc Graw Hill co., pp. 197-231.
- Holme, A. B., Alex, V. A. 2004. A Pooled Analysis Of Studies With A New Calcipotriene/Betamethasone Two-Compound Product in Psoriasis Vulgaris. *Journal Of The American Academy Of Dermatology*. 8(2):421-8. doi: 10.1016/j.jaad.2003.10.007.
- Hossler, E.W., Wood G.C., Still C.D., Mowad C.M., Maroon M.S. 2013. The Effect of Weight Loss Surgeru on The Severity of Psoriasis. *British Journal of Dermatology*. 168(3):660-1. doi: 10.1111/j.1365-2133.2012.11211.x.
- Icen, M., Crowson C.S., McEvoy M.T., Dann F.J., Gabriel S.E., Maradit K.H. 2009. Trends in Incidence of Adult Onset Psoriasis Over Three Decades: A Population Based Study. *J Am Acad Dermatol*. 60(3):394-401. doi: 10.1016/j.jaad.2008.10.062.
- Jaehwan, K., Krueger J.G. 2017. IL-17A is Essential for Cell Activation and Inflammatory Gene Circuits in Subject with Psoriasis. *J Allergy Clin Immunol*. 130(1):1181-1189. doi: 10.1016/j.jaci.2012.04.024.
- Kalkan, G., Serap A.K. 2013. The Association Between Psoriasis and Cardiovascular Disease. *Eur J Gen Med*. 10(1):10-16. doi: 10.29333/ejgm/82298.
- Khadka, D. K., Agrawal S., Dhali, T. K. 2015. Methotrexate Plus Narrow Band Ultraviolet B Versus Methotrexate Alone In The Treatment Of Moderate To Severe Plaque Psoriasis: A Randomized Clinical Trial. *Nepal Journal Of Dermatology*. 13(1):12-23. doi: 10.3126/njdvl.v13i1.14298.
- Kozub, P., Simaljakova M. 2011. Systemic Therapy of Psoriasis: Methotrexate. *Bratisl Lek Listy* 112: 390–94.
- Mayburi, C., Samarasekera, E., Douiri A., Barker J., Smith C. 2014. Diagnostic Accuracy of Noninvasive Markers of Liver Fibrosis in Patients with Psoriasis Taking Methotrexate: A Systematic Review and Meta-Analysis. *British Journal of Dermatology* 170(1): 1237–1247. doi: 10.1111/bjd.12905.
- Mazlin, M.B., Chang C.C., Baba R. 2012. Comorbidities Associated with Psoriasis. *Med J Malaysia*. 67(5):518-21.

- Moningka, A., Renate T.K., Nurdjannah J.N. 2015. Profil Psoriasis di Poliklinik Kulit dan Kelamin RSUD Prof. R. D. Kandou Manado periode Januari-Desember 2012. *Journal E Clinic*. 3(2):646-650. doi: 10.35790/ec1.3.2.2015.8384.
- Nakamura, M., Benjamin F., Tina B. 2016. Recent Advances in Phototherapy for Psoriasis. *Research*. 5: 16-84. doi:10.12688/f1000research.8846.1.
- National Psoriasis Foundation. 2015. *Psoriasis*. National Psoriasis Foundation.
- Ogawa, E., Yuki S., Akane M., Ryuhei O. 2018. Pathogenesis of Psoriasis and Development of Treatment. *Journal of Dermatology* 45: 264–72. doi: 10.1111/1346-8138.14139.
- Oliveira, M.F., Rocha B.O., Duarte, G.V. 2015. Psoriasis: Classical And Emerging Comorbidities. *An Bras Dermatol*. 90(1):9-20. doi: 10.1590/abd1806-4841.20153038.
- Operacz, C.M., Przytocka, S.A. 2014. The Possibilities and Principles of Methotrexate Treatment of Psoriasis - The Updated Knowledge. *Postepy Dermatologii i Alergologii* 31: 392–400. doi: 10.5114/pdia.2014.47121.
- Parisi, R., Symmons D. P. M., Griffiths C. E. M., Ashcroft D. M. 2013. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. *J Invest Dermatol*. 133: 377-385. doi: 10.1038/jid.2012.339.
- Park, J.H., Young J.P., Sue K.K., Ji E.K., Hee YoY.K., Eun S.L., *et al.* 2016. Histopathological Differential Diagnosis of Psoriasis and Seborrheic Dermatitis of the Scalp. *Annals of Dermatology* 28: 427–32. doi: 10.5021/ad.2016.28.4.427.
- Pathirana, D., Ormerod A.D., Saiag P., Smith C., Spuls P.I., Barker J., *et al.*, 2009. European S3-Guideline on The Systemic Treatment of Psoriasis Vulgaris. *Journal of The European Academy of Dermatology and Venereology*. 23(2):1-69. doi: 10.1111/jdv.14454.
- PERDOSKI. 2017. *Panduan Praktik Klinis Bagi Dokter Spesialis Kulit dan Kelamin di Indonesia*. Perhimpunan Dokter Spesialis Kulit dan Kelamin 420 Hal.
- Pratiwi, K.D., Damayanti D. 2018. Profil Psoriasis Vulgaris di RSUD Dr. Soetomo Surabaya: Studi Retrospektif. *Berkala Ilmu Kesehatan Kulit dan Kelamin*. 3:248-254. doi: 10.20473/bikk.v30.3.2018.248-254.
- Racz E., Errol P.P. 2009. Molecular Pathophysiology of Psoriasis and Molecular Targets of Anti Psoriatic Therapy. *Experts Review in Molecular Medicine*. 11:38-42. doi: 10.1017/S146239940900129X.

- Radensek, S., Vita D. 2017. Pharmacogenetics of Psoriasis Treatment. *Intech*. 10:673-71.
- Seebode, C., Lehman J., Emmert S. 2016. Photocarcinogenesis and Skin Cancer Prevention Strategies. *Anticancer Res* 36(3): 1371-1378.
- Sindhuri, K., Virupakshappa T., Anant A.T. 2019. Comparative Study of Oral Methorexate and Narrow Band Ultraviolet B in Chronic Plaque Psoriasis: A Study from Urban Karnataka. *International Journal of Research in Dermatology*. 5(2):1-5. doi: 10.18203/issn.2455-4529.IntJResDermatol20190480
- Singh, R.K., Kristina M.L., Margareth V. J., Mio N., Derya U., Benjamin F., Michael A., Tian H.Z., Tina B., Wilson L. 2016. The Patient's Guide to Psoriasis Treatment. Part 1: UVB Phototherapy. *Dermatology and Therapy* 6: 307–13. Doi: 10.1007/s13555-016-0129-2.
- Takeshita, J., Sungat G., Sinéad M. L., Nehal N. M., Alexis O., Abby S.V.V., Joel M.G. 2017. Psoriasis and Comorbid Diseases. *Journal of the American Academy of Dermatology* 76: 377–90. doi: 10.1016/j.jaad.2016.07.064.
- Thamtono, Y. 2016. Hubungan Psoriasis dengan Komorbiditas Kardiovaskuler. *Cermin Dunia Kedokteran*. 43:112-115.
- Tsakok, E A. 2018. Subcutaneous Methotrexate in Patients with Moderate to Severe Psoriasis: A Critical Appraisal. *British Journal of Dermatology*. 179:50-53. doi: 10.1111/bjd.16424.
- Wong, T., Leon H., Wilson L. 2013. Phototherapy in Psoriasis: A Review of Mechanisms of Action. *Journal of Cutaneous Medicine and Surgery* 17: 6–12. doi: 10.2310/7750.2012.11124.
- World Health Organization. 2016. *Global Report on Psoriasis*. WHO Press. Geneva.
- Khaja, A., Shkodrani E., Frangaj S., Kuneshka L., Vasili E. 2014. An Epidemiological Study on Trigger Factors and Quality of Life in Patients with Psoriasis. *Master Sociomed*. 26(3):168-171. doi: 0.5455/msm.2014.26.168-171.
- Yélamos, O., Lluís P. 2015. Systemic Methotrexate for the Treatment of Psoriasis. *Expert Review of Clinical Immunology* 11(3): 553–563. doi: 10.1586/1744666X.2015.1026894.
- Zhang, P., Mei X.W. 2018. A Clinical Review of Phototherapy for Psoriasis. *Lasers in Medical Science* 33: 173–80. doi: 10.1007/s10103-017-2360-1.